Guided Therapeutics (GTHP) Return on Capital Employed (2012 - 2025)
Guided Therapeutics recorded quarterly Return on Capital Employed of 42.95% in Q4 2025, up 8.52% quarter-over-quarter from 39.58% in Q3 2025, and down 61.0% year-over-year from 110.13% in Q4 2024.
Guided Therapeutics' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 42.95% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 61.0% year-over-year to 42.95%; the TTM figure through Dec 2025 stood at 42.95% (down 61.0% YoY), while the FY2025 annual figure was 44.88%, down 63.0% from the prior year.
- Return on Capital Employed came in at 42.95% for Q4 2025 at Guided Therapeutics, up from 39.58% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 427.0% in Q1 2023 to a low of 22.15% in Q1 2021.
- A 5-year average of 97.87% and a median of 55.27% in 2021 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 36926 bps in 2023 and plunged 34797 bps in 2024, its largest moves.
- Guided Therapeutics' Return on Capital Employed stood at 60.65% in 2021, then surged by 339 bps to 266.45% in 2022, then tumbled by 57 bps to 113.83% in 2023, then slumped by 62 bps to 43.56% in 2024, then retreated by 1 bps to 42.95% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 42.95%, 39.58%, and 41.89% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 7.36% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 11.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 7.62% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 24.24% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 9.30% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 11.57% |
| 10 | Guided Therapeutics | - | - | 458,000.00 | 42.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 42.95% |
| Sep 30, 2025 | 39.58% |
| Jun 30, 2025 | 41.89% |
| Mar 31, 2025 | 45.78% |
| Dec 31, 2024 | 43.56% |
| Sep 30, 2024 | 43.14% |
| Jun 30, 2024 | 48.68% |
| Mar 31, 2024 | 79.03% |
| Dec 31, 2023 | 113.83% |
| Sep 30, 2023 | 144.00% |
| Jun 30, 2023 | 195.16% |
| Mar 31, 2023 | 427.00% |
| Dec 31, 2022 | 266.45% |
| Sep 30, 2022 | 114.64% |
| Jun 30, 2022 | 50.16% |
| Mar 31, 2022 | 57.74% |
| Dec 31, 2021 | 60.65% |
| Sep 30, 2021 | 68.10% |
| Jun 30, 2021 | 52.80% |
| Mar 31, 2021 | 22.15% |
| Dec 31, 2020 | 13.78% |
| Sep 30, 2020 | 12.93% |
| Jun 30, 2020 | 12.08% |
| Mar 31, 2020 | 10.91% |
| Dec 31, 2019 | 8.04% |
| Sep 30, 2019 | 10.78% |
| Jun 30, 2019 | 11.10% |
| Mar 31, 2019 | 12.59% |
| Dec 31, 2018 | 14.58% |
| Sep 30, 2018 | 17.94% |
| Jun 30, 2018 | 24.30% |
| Mar 31, 2018 | 25.41% |
| Dec 31, 2017 | 27.85% |
| Sep 30, 2017 | 34.28% |
| Jun 30, 2017 | 30.59% |
| Mar 31, 2017 | 39.06% |
| Dec 31, 2016 | 50.53% |
| Sep 30, 2016 | 66.81% |
| Jun 30, 2016 | 96.29% |
| Mar 31, 2016 | 170.25% |
| Dec 31, 2015 | 228.66% |
| Sep 30, 2015 | 453.30% |
| Jun 30, 2015 | 513.11% |
| Mar 31, 2015 | 340.96% |
| Dec 31, 2014 | 706.89% |
| Sep 30, 2014 | 2,255.30% |
| Jun 30, 2014 | -1,019.54% |
| Mar 31, 2014 | -3,474.49% |
| Dec 31, 2013 | -488.79% |
| Sep 30, 2013 | -312.94% |
| Jun 30, 2013 | -242.69% |
| Mar 31, 2013 | -259.10% |
| Dec 31, 2012 | -240.57% |
| Sep 30, 2012 | -400.40% |
| Jun 30, 2012 | -3,465.01% |
| Mar 31, 2012 | -461.16% |